Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035

Analyze hepatocellular carcinoma epidemiology with 10-year forecasts for incident and prevalent cases by age, sex, disease stage, risk factors, cirrhosis, and biomarkers.

Why Does Hepatocellular Carcinoma Epidemiology Matter?

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for approximately 90% of primary liver cancers. Understanding the size and characteristics of the HCC patient population is important for assessing disease burden and planning therapeutic strategies.

HCC has a high mortality rate and is the third leading cause of cancer deaths annually worldwide. This epidemiology model provides a 10-year forecast of diagnosed incident cases, five-year diagnosed prevalent cases, and all-time diagnosed prevalent cases, with detailed segmentation by age, sex, disease stage, risk factors, cirrhosis status, and biomarkers.

You can use this report to:

• Understand the epidemiological burden of HCC
• Forecast diagnosed HCC patient populations over 10 years
• Assess HCC cases by age and sex
• Analyze patient populations by disease stage
• Understand the impact of key HCC risk factors
• Compare cirrhotic and non-cirrhotic HCC populations
• Assess HCC populations by biomarkers
• Quantify patient populations to support product and launch planning
• Identify patient segments relevant to HCC therapeutics
  

Key Insights in the Hepatocellular Carcinoma Epidemiology Landscape

The report highlights key developments in HCC epidemiology, including:

• Hepatocellular carcinoma is the most common primary liver cancer
• HCC accounts for approximately 90% of all primary liver cancers
• HCC is associated with a high mortality rate
• Major risk factors include hepatitis B virus (HBV), hepatitis C virus (HCV), and high alcohol consumption
• Cirrhosis is a crucial factor in the development of HCC
• HCC occurs in approximately 85% of patients with liver cirrhosis
• HCC is nearly three times as common in men as in women
• A 10-year epidemiological forecast of diagnosed incident HCC cases is provided
• Five-year diagnosed prevalent cases are modeled
• All-time diagnosed prevalent cases are included
• Diagnosed incident cases are segmented by age from 18 through 85 years and older
• Incident cases are segmented by sex
• HCC cases are segmented by BCLC stage
• Patient populations are assessed by Child-Pugh and HKLC stages
• HCC risk factors covered include hepatitis B, hepatitis C, MASLD/MASH, and alcohol
• Cases are segmented into cirrhotic and non-cirrhotic HCC
• HCC populations are analyzed by biomarkers
• All-time diagnosed prevalent cases are segmented by BCLC stage

Scope

What Will You Learn from This Hepatocellular Carcinoma Epidemiology Analysis Report?

This report provides insight into:

• Diagnosed incident HCC cases
• Five-year diagnosed prevalent HCC cases
• All-time diagnosed prevalent HCC cases
• Ten-year epidemiological forecasts
• HCC cases by age group
• HCC cases by sex
• HCC populations by BCLC stage
• HCC populations by Child-Pugh stage
• HCC populations by HKLC stage
• HCC risk-factor segmentation
• HBV-associated HCC
• HCV-associated HCC
• MASLD/MASH-associated HCC
• Alcohol-associated HCC
• Cirrhotic and non-cirrhotic HCC populations
• HCC biomarker segmentation
• Patient population trends relevant to HCC therapeutics

Who Should Buy This Hepatocellular Carcinoma Epidemiology Analysis Report?

This report may be valuable for:

• Pharmaceutical companies
• Biopharmaceutical companies
• Oncology drug developers
• Liver cancer therapeutics companies
• Clinical development teams
• Commercial strategy teams
• Market access teams
• Epidemiology and medical affairs teams
• Corporate strategy and business development teams
• Healthcare and life sciences investors
• Industry and competitive intelligence teams
• Drug pricing and market planning teams
• Management consultants
• Senior executives and decision-makers
  

  

How Companies Use This Hepatocellular Carcinoma Epidemiology Analysis

Pharmaceutical and healthcare companies can use the report to:

• Quantify HCC patient populations
• Forecast diagnosed incident and prevalent cases
• Assess patient populations by age and sex
• Identify demographic segments relevant to HCC therapeutics
• Understand HCC populations across disease stages
• Assess the prevalence of key HCC risk factors
• Compare cirrhotic and non-cirrhotic patient populations
• Evaluate HCC populations by biomarkers
• Support product development and clinical planning
• Inform pricing and market access strategies
• Support launch planning
• Identify patient segments for sales and marketing activities
• Develop commercial and business strategies
• Assess epidemiological trends that may influence the HCC therapeutic market

Reasons to Buy

Benchmark the Hepatocellular Carcinoma Patient Population

This report enables stakeholders to benchmark:

• Diagnosed incident HCC cases
• Five-year diagnosed prevalent cases
• All-time diagnosed prevalent cases
• HCC cases by age
• HCC cases by sex
• BCLC stage distribution
• Child-Pugh stage distribution
• HKLC stage distribution
• HCC risk-factor populations
• Cirrhotic versus non-cirrhotic HCC
• HCC biomarker populations
• Patient population trends over the forecast period

Built on GlobalData Business Intelligence

The model combines epidemiological analysis with detailed patient segmentation to provide a structured view of the HCC population.

Coverage includes diagnosed incident and prevalent cases, with segmentation across age, sex, disease stage, risk factors, cirrhosis status, and biomarkers. This provides stakeholders with quantitative insight into the patient populations relevant to HCC therapeutic development and commercialization.

Act Now to Identify Opportunities in Hepatocellular Carcinoma

Understanding the size and characteristics of the HCC patient population can help pharmaceutical and healthcare companies assess therapeutic opportunities, plan product strategies, and identify relevant patient segments.

Use this epidemiology model to forecast diagnosed HCC cases, assess patient populations by age, sex and disease stage, understand key risk factors, and support product development, pricing, launch planning, sales, and marketing strategies.